– Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 –– Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 –– Raising 2026 Full Year Guidance –– Successful Debt Repricing in July Reduces Interest Cost – BRIDGEWATER, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the second quarter ended June 30, 2026. “Amneal delivered strong, broad-based performanc ...